Home | imu

Platform

IMU is a discovery engine mapping the immune system in unprecedented detail and scale to deliver unique, systems-level immune insights

Massively scalable, high-resolution low cost immunophenotyping
- +2,000 discrete cell subsets capturing a systems-level immune profile
- +40 million data points from 2ml of blood
Proprietary real time machine learning analytics
- Rapid interpretation of complex immune systems and its role in disease
- Predictive and diagnostic models of immune system orchestration and disease status
Broad, deep and unique immune database
- Powered by an extensive +1,500 database from healthy donors, biobanks and research projects
- Aggregating other biomarkers to enable broad interrogation of immune-mediated disease

Partnerships

IMU is partnering to unlock the potential of the immune system and advance immune medicines

Patient stratification

The right patient for the right drug

Immune medicine is revolutionising cancer treatment but only works in ~20% of patients. This is due to the huge variation in immune competence across patient groups. IMU can stratify patients by systemic immune signatures to enhance our understanding of which patients will respond to treatment, how patients can be better primed before treatment and to guide the better design of combination therapies.

Patient monitoring

Non-invasive, frequent patient analysis

The IMU platform requires only 2ml of fresh or cryopreserved blood samples. This allows for regular, cost-effective monitoring of patients’ immune systems for signatures of treatment response, immune reconstitution after lymphodepletion, irTOX, disease progression or relapse. The low material requirements and real time data analysis allow IMU to fit seamlessly into clinical workflows.

Cell therapy production

Donor stratification by immune signatures

Immune cells do not exist in isolation in vivo; rather, the immune environment from which they derive can shed light on how effective the cells will be in vitro. IMU can stratify cell therapy donors by systemic immune analysis that permits the identification of specific signatures correlating with successful expansion and functional endpoints.

How we do it

The science behind

In-house sample processing and data generation
We aim to empower people to live healthier lives and to change the phase of preventive medicine. We determine on a cell by cell basis the level of activation and exhaustion and ultimately how well equiped they are to function properly.
Powered by healthy immune data and research collaborators
We have built a massive immune database that allows us to account for the immune variation. This growing database is able to identify nuanced immune signatures relating to disease, treatment response, lifesytle and physiological factors.
Propietary analytics with machine learning
Innovative machine learning analytics powers real-time cell classification and contextualisation and understanding of individual immune profiles and signatures in relation to our ever growing immune health database.

History

About us

IMU was founded on the belief that deep immunophenotyping at population level scale powered by machine learning could unlock the power of the immune system to help develop the next generation of immune medicines. We believe that in the future, no medical decision will be made without an understanding of a patient's immune system.
‍
Contact us to learn more.

Experience

The team

We’re a team of healthcare experts, immunologists, clinicians, technologists, developers and researchers with a bold ambition: To revolutionise our understanding of the immune system and derive tangible, actionable value from that understanding.
‍
Learn more.

IMU team

Dr. Adam Laing

PhD

Co-founder & Chief Scientific Officer

Dr. Thomas Hayday

PhD

Co-founder & Chief Research Officer

Dr. Jennie Yang

PhD

R&D and QA Lead

Jeremy Mason

Head of Data Science

Mario Cantero

MBA MS

Co-founder & Chief Executive Officer

Pelle Ullberg

Software Engineer

Chief Technology Officer

Arnaud Haines

MBA MS

Business Development

Dr. Eduardo de Paiva

PhD

Data Science Lead

Gabija Drazdauskaitė

Senior Research Assistant, R&D

Clara Dubois

BISM

Strategy & Operations

Advisors

Andrew Johnson

MBA MS

Chairman
Partner at Beaumont Capital

Tim Haines

MBA

Investor & Advisor
Managing Partner at Abingworth

Carina Szpilka

MBA

Investor & Advisor
General Partner at K Fund

Immune powered precision medicine